During the past decade, Centre Azuréen de Cancérologie conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Azuréen de Cancérologie" #1 sponsor was "ARCAGY/ GINECO GROUP" with 10 trials, followed by "UNICANCER" with 9 trials sponsored, "Centre Antoine Lacassagne" with 3 trials sponsored, "The Lymphoma Academic Research Organisation" with 3 trials sponsored and "Federation Francophone de Cancerologie Digestive" with 3 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Azuréen de Cancérologie" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "Bayer" with 2 trials as a collaborator, "GlaxoSmithKline" with 2 trials as a collaborator, "Aarhus University Hospital" with 1 trials as a collaborator and "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 1 trials as a collaborator. Other collaborators include 35 different institutions and companies that were collaborators in the rest 45 trials.

According to Clinical.Site data, the most researched conditions in "Centre Azuréen de Cancérologie" are "Breast Cancer" (6 trials), "Ovarian Cancer" (5 trials), "Prostate Cancer" (3 trials), "Adenocarcinoma of Prostate" (1 trials) and "Bladder Cancer" (1 trials). Many other conditions were trialed in "Centre Azuréen de Cancérologie" in a lesser frequency.

Most popular intervention types in "Centre Azuréen de Cancérologie" are "Drug" (31 trials), "Radiation" (8 trials), "Other" (5 trials), "Procedure" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Capecitabine" (5 trials), "Paclitaxel" (3 trials), "Placebo" (3 trials), "Bevacizumab" (2 trials) and "Trastuzumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Centre Azuréen de Cancérologie" are 20 trials for "Female" genders, 13 trials for "All" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Centre Azuréen de Cancérologie". undefined are not yet recruiting, 10 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Centre Azuréen de Cancérologie, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Centre Azuréen de Cancérologie, 1 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 6 trials that are defined as “Not Applicable".